Dr. Middleman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
310 E Highway 67
Duncanville, TX 75137Phone+1 972-283-2389Fax+1 972-283-2473
Education & Training
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1969 - 1971
- UPMC Medical EducationResidency, Internal Medicine, 1968 - 1969
- UPMC Medical EducationInternship, Internal Medicine, 1965 - 1966
- University of Pittsburgh School of MedicineClass of 1965
Certifications & Licensure
- TN State Medical License 2023 - 2025
- OH State Medical License 2018 - 2024
- TX State Medical License 1969 - 2024
- WV State Medical License 2018 - 2023
- ID State Medical License 2011 - 2022
- AZ State Medical License 2017 - 2021
- VT State Medical License 2018 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- 24 citationsA randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.Adam Brufsky, Karen Hoelzer, Thaddeus Beck, Robert C. Whorf, Mark Keaton
Clinical Breast Cancer. 2011-08-01 - 57 citationsA Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung CancerThomas J. Lynch, David Fenton, Vera Hirsh, David Bodkin, Edward L. Middleman
Journal of Thoracic Oncology. 2009-08-01 - 156 citationsRandomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–S...Charles A. Butts, David Bodkin, Edward L. Middleman, Craig W. Englund, David W. Ellison
Journal of Clinical Oncology. 2007-12-20
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: